Pulmonary embolism (PE) in the setting of COVID-19 is related to the procoagulant state as evidenced by the increased d-dimer levels and in situ thrombosis [1,2] and it usually involves the segmental/subsegmental arteries [2]. Some data have shown that mortality is higher among patients with COVID-19 associated PE compared with non-COVID-19 PE [3]. The COVID-19 pandemic has led to marked reductions in cardiovascular testing in the United States (US) and worldwide [4]. However, the impact of the COVID-19 pandemic on the diagnosis and management of PE is not well studied.
